Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPHASE PREMARIN CYCRIN 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPHASE PREMARIN CYCRIN 14 14.
NORGESTIMATE AND ETHINYL ESTRADIOL vs PREMPHASE (PREMARIN;CYCRIN 14/14)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
PREMPHASE combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which regulate gene transcription and produce effects in tissues such as the endometrium, breast, and bone. Medroxyprogesterone acetate is a progestin that induces secretory changes in the endometrium and reduces the risk of endometrial hyperplasia associated with estrogen therapy.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
One tablet daily (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) for 14 days, followed by one tablet daily (conjugated estrogens 0.625 mg) for 14 days; continuous cycling. Oral administration.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Conjugated estrogens: terminal half-life 10–24 h (accumulation with daily dosing). MPA: terminal half-life 12–33 h (mean ∼17 h).
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Conjugated estrogens and MPA are primarily excreted in urine (∼90% as glucuronide and sulfate conjugates) and feces (∼10% as unabsorbed drug and biliary metabolites).
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination